Immunic (IMUX) Liabilities and Shareholders Equity (2013 - 2026)

Immunic (IMUX) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $189.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 824.89% year-over-year to $189.7 million; the trailing twelve-month figure through Mar 2026 stood at $315.9 million (up 48.58% YoY), and the FY2025 full-year result was $24.1 million, down 41.15% from the prior year.
• Liabilities and Shareholders Equity improved to $189.7 million in Q1 2026, from $24.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $189.7 million in Q1 2026 to a low of $20.5 million in Q1 2025.
• A 5-year average of $87.6 million and a median of $86.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 80.3% in 2025 and jumped 824.89% in 2026, its largest moves.
• Tracing IMUX's Liabilities and Shareholders Equity over 5 years: stood at $127.8 million in 2022, then sank by 57.5% to $54.3 million in 2023, then decreased by 24.74% to $40.9 million in 2024, then plunged by 41.15% to $24.1 million in 2025, then soared by 688.88% to $189.7 million in 2026.
• Business Quant data shows IMUX's Liabilities and Shareholders Equity at $189.7 million in Q1 2026, $24.1 million in Q4 2025, and $40.7 million in Q3 2025.